Stay updated with breaking news from Robert Barrow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mind Medicine Inc. said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically...
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers:
-inc-logo.png&w=240&h=240&zc=2){kind=logo}
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Mind […]
– 53 participants enrolled across two sites – ...
– Preclinical data in ASD model demonstrate the differences between MM-402 , S-MDMA and Racemic MDMA with enhanced pro-social effects and reduced hyperactivity – ...